Dexcom director granted 5,841 RSUs on Sept. 10

Dexcom director Glenn S. Boehnlein received a time-vested equity grant of 5,841 restricted stock units, increasing his reported direct and trust holdings in DXCM.

Available on EDGAR 09/10/2026 - 04:41 PM EDT Accepted by SEC EDGAR 09/10/2026 - 04:40 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

DEXCOM INC (symbol: DXCM) is the issuer of record for a Form 4 filing submitted to the SEC. Boehnlein Glenn S reported acquisition or exercise transactions in this Form 4 filing.

DEXCOM INC (DXCM) reported that director Glenn S. Boehnlein received a grant of 5,841 restricted stock units of common stock on September 10, 2026. The award is exempt from Section 16b-3 and vests in three equal annual installments from the grant date, representing a contingent right to receive one share per unit. After this grant, Boehnlein holds 5,841 shares directly and 42 shares indirectly through the Boehnlein 2017 Trust, for which he and his spouse are co-trustees. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 5,841 shares

Grant/Award 1 txn

Insider Boehnlein Glenn S

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1	5,841	$0.00	$0.00
Holding	Common Stock F2	--	--	--

Holdings After Transaction: Common Stock — 5,841 shares (Direct); Common Stock — 42 shares (Indirect, By Trust)

Footnotes (2)

1. F1. Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.
2. F2. Shares are held by the Boehnlein 2017 Trust, with respect to which the Reporting Person and the Reporting Person's spouse are co-trustees.

Key Figures

Restricted stock units granted: 5,841 units Direct common stock holdings after grant: 5,841 shares Indirect common stock holdings by trust: 42 shares +2 more

5 metrics

Restricted stock units granted 5,841 units Grant of restricted stock units to director Glenn S. Boehnlein on September 10, 2026

Direct common stock holdings after grant 5,841 shares Shares of Dexcom common stock held directly by Glenn S. Boehnlein after the reported grant

Indirect common stock holdings by trust 42 shares Shares held by the Boehnlein 2017 Trust, reported as indirectly owned

Vesting schedule installments 3 installments Restricted stock units vest in three equal annual installments from the grant date

Rule 10b5-1 plan status No plan reported Document-level Rule 10b5-1 checkbox is not affirmed for these transactions

Key Terms

restricted stock units, Section 16b-3, contingent right, co-trustees

4 terms

restricted stock units financial

"Represents a grant of restricted stock units that are exempt from Section 16b-3"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

Section 16b-3 regulatory

"Represents a grant of restricted stock units that are exempt from Section 16b-3"

contingent right financial

"Restricted stock units represent a contingent right to receive one share"

co-trustees other

"the Reporting Person and the Reporting Person's spouse are co-trustees"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity award did Dexcom (DXCM) director Glenn S. Boehnlein receive?

Glenn S. Boehnlein received a grant of 5,841 restricted stock units of Dexcom common stock on September 10, 2026. Each unit represents a contingent right to receive one share of Dexcom, Inc. common stock, subject to vesting conditions.

How do the new Dexcom (DXCM) restricted stock units vest for Glenn S. Boehnlein?

The 5,841 restricted stock units granted to Glenn S. Boehnlein vest in three equal annual installments starting from the September 10, 2026 grant date. Vesting is time-based, and each vested unit entitles him to receive one share of Dexcom common stock.

What are Glenn S. Boehnlein’s reported Dexcom (DXCM) share holdings after this Form 4?

After the reported transactions, Glenn S. Boehnlein holds 5,841 shares directly. In addition, 42 shares are held indirectly through the Boehnlein 2017 Trust, with Boehnlein and his spouse serving as co-trustees.

Are Glenn S. Boehnlein’s Dexcom (DXCM) restricted stock units exempt from Section 16 reporting rules?

The filing states the award represents a grant of restricted stock units exempt from Section 16b-3. These units are subject to vesting over three years and represent a contingent right to receive one share of Dexcom common stock per unit.

Does the Dexcom (DXCM) Form 4 indicate trades under a Rule 10b5-1 plan?

No. The document-level Rule 10b5-1 checkbox is unchecked, and there is no footnote stating that the reported transactions were made under a Rule 10b5-1 trading plan.

How are the Dexcom (DXCM) shares in the Boehnlein 2017 Trust characterized?

The filing states that 42 shares of Dexcom common stock are held by the Boehnlein 2017 Trust. Glenn S. Boehnlein and his spouse are co-trustees, and these shares are reported as indirectly owned.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Boehnlein Glenn S

(Last) (First) (Middle)

6340 SEQUENCE DRIVE

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DEXCOM INC [ DXCM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/10/2026		A		5,841(1)	A	$0	5,841	D
Common Stock								42	I	By Trust(2)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents a grant of restricted stock units that are exempt from Section 16b-3 and are subject to vesting in three equal annual installments from the date of grant. Restricted stock units represent a contingent right to receive one share of DexCom, Inc. Common Stock.

2. Shares are held by the Boehnlein 2017 Trust, with respect to which the Reporting Person and the Reporting Person's spouse are co-trustees.

Remarks:

	/s/ Jereme M. Sylvain, as Attorney-in-Fact for Glenn S. Boehnlein	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)